The spectrum of type i cryoglobulinemia vasculitis: New insights based on 64 cases

Medicine (United States)

Volumn 92, Issue 2, 2013, Pages 61-68

  Terrier, Benjamin ^a   Karras, Alexandre ^b   Kahn, Jean Emmanuel ^c   Le Guenno, Guillaume ^d   Marie, Isabelle ^e   Benarous, Lucas ^f   Lacraz, Adeline ^g   Diot, Elisabeth ^h   Hermine, Olivier ⁱ   De Saint Martin, Luc ^j   Cathébras, Pascal ^k   Leblond, Véronique ^a   Modiano, Philippe ^l   Léger, Jean Marc ^a   Mariette, Xavier ^m   Senet, Patricia ⁿ   Plaisier, Emmanuelle ⁿ   Saadoun, David ^a   Cacoub, Patrice ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c FOCH HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ HÔPITAL TENON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CHLORAMBUCIL; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CRYOGLOBULINEMIA; CRYOGLOBULINEMIA VASCULITIS TYPE 1; FEMALE; GLOMERULONEPHRITIS; HEALTH CARE SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; CRYOGLOBULINEMIA; FEMALE; FRANCE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULITIS;

EID: 84874931606     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e318288925c     Document Type: Article

References (27)

1. Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121: 749-757.
2. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57: 775-788.
3. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42: 2204-2212. (Pubitemid 30263607)
4. Calabrese C, Faiman B, Martin D, Reu F, Calabrese LH. Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. J Clin Rheumatol. 2011;17: 145-147.
5. Cem Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol. 2005;84: 609-613. (Pubitemid 41194550)
6. Dimopoulos MA, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. How we treat Waldenstrom's macroglobulinemia. Haematologica. 2005;90: 117-125.
7. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55: 4-13. (Pubitemid 34081673)
8. Ghobrial IM, Uslan DZ, Call TG,Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77: 329-330. (Pubitemid 39578310)
9. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, Franklin EC. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980;69: 287-308. (Pubitemid 10036826)
10. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book. Hematology Am Soc Hematol Educ Program. 2009;2009(1): 523-531.
11. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337: 1512-1523. (Pubitemid 27495778)
12. Lin RJ, Curran JJ, Zimmerman TM, Song J, Niewold TB, Sweiss NJ. Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol. 2010;16: 90-91.
13. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G, Candela M, Ferri C, Gabrielli A, Mazzaro C, Migliaresi S, Mussini C, Ossi E, Quintiliani L, Tirri G, Vacca A, and the GISC. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995;88: 115-126.
14. Morra E. Cryoglobulinemia. ASH Education Book. Hematology Am Soc Hematol Educ Program. 2005;2005(1): 368-372.
15. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford). 2005;44: 410-411.
16. Pandrangi S, Singh A, Wheeler DE, Rossi NF. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol. 2008;4: 393-397. (Pubitemid 351913687)
17. Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, Karras A, Salliot C, Suarez F, Avet-Loiseau H, Alyanakian MA, Nawakil CA, Park S, Tamburini J, Roux C, Bouscary D, Sparsa L. Type I cryoglobulinemia in multiple myeloma: a rare entity. Analysis of clinical and biological characteristics of 7 cases and review of the literature. Leuk Lymphoma. 2012; EApril 19, 2012; Epub ahead of print.
18. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379: 348-360.
19. Rosenthal E, Pesce A, Karsenti JM, Allieri-Rosenthal MA, Cassuto JP. Polyneuropathy and vasculitis associated with IgG type I cryoglobulinemia can be treated with the anti-CD20 monoclonal antibody (rituximab). Blood. 2001;98(Suppl):292b.
20. Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166: 2101-2108. (Pubitemid 44631398)
21. Sampson A, Callen JP. The cutting edge: thalidomide for type 1 cryoglobulinemic vasculopathy. Arch Dermatol. 2006;142: 972-974. (Pubitemid 44268472)
22. Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with iGmkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60: 3848-3855.
23. Spizzo G, Mitterer M, Gunsilius E. Bortezomib for the treatment of refractory type-1 cryoglobulinaemia. Br J Haematol. 2010;150: 235-237.
24. Talamo G, Claxton D, Tricot G, Fink L, Zangari M. Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol. 2008;83: 883-884.
25. Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathebras P, Combe B, de Jaureguiberry JP, Meyer O, Schaeverbeke T, Somogyi A, Tricot L, Zenone T, Ravaud P, Gottenberg JE, Mariette X, Cacoub P. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62: 1787-1795.
26. Terrier B, Semoun O, Saadoun D, Sene D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63: 1748-1757.
27. Trejo O, Ramos-Casals M, Garcia-Carrasco M, Yague J, Jimenez S, de la Red G, Cervera R, Font J, Ingelmo M. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80: 252-262.. (Pubitemid 32703064)